<DOC>
	<DOCNO>NCT02108106</DOCNO>
	<brief_summary>This dose escalation study conduct healthy volunteer . Multiple cohort volunteer receive ascend oral dos AG-348 evaluate safety tolerability single oral dose AG-348 , pharmacokinetics ( PK ) single dose AG-348 , pharmacodynamic profile AG-348 specific biomarkers assess blood .</brief_summary>
	<brief_title>A Phase I Study AG-348 Healthy Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy adult male female subject 18 60 year , good general health able understand consent complete study procedure . Female subject nonchild bear potential ( surgically sterile postmenopausal confirm age [ 50 year ] , amenorrhea 12 consecutive month FSH ) . Male subject vasectomize must agree use contraception 30 day dose . Subjects body weight ≥50 kg ; BMI ≥18.5 ≤32 kg/m2 . Subjects nonsmoker use nicotine containing product least 3 month prior screen . Subjects must willing refrain caffeine xanthene containing product ( chocolate ) prior dose 72 hour dose . Subjects must agree refrain strenuous exercise prior admission final visit . Subjects must refrain use alcohol start 7 day prior admission final visit . Subjects must agree donate blood product duration study participation . Subjects previously receive AG348 . Subjects clinically relevant screen laboratory test . Female subject childbearing potential . Male subject QTcF interval ECG &gt; 450 msec , female subject QTcF interval ECG &gt; 470 msec . Subjects history serious mental illness . Subjects clinically relevant medical history preexist medical condition would interfere absorption , metabolism excretion study drug . Subjects history primary malignancy ( cancer ) . Exceptions certain skin cancer , cervical cancer situ cancer curatively treat without evidence disease minimum 1 year . Subjects glucose6phosphatedehydrogenase ( G6PD ) deficiency . Subjects positive hepatitis B , hepatitis C HIV . Subjects undergone surgery 6 month prior screen . Subjects history illicit drug use alcoholism within last year . Subjects participate concurrent clinical trial investigational drug , receive another investigational agent within last 2 month . Subjects condition would make subject unsuitable enrollment , could interfere subject 's participation completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>safety tolerability</keyword>
	<keyword>pharmacokinetic study</keyword>
</DOC>